|
R S S F e e d s |
|
Pharma Industry / Biotech Industry News From Medical News Today
|
Latest Pharma Industry / Biotech Industry News From Medical News Today.
|
-
Galenea And Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration
Galenea Corp. and Otsuka Pharmaceutical Co., Ltd. announced today the extension and expansion of their research and development collaboration. The two companies have been working together since January 2005 to discover and develop novel therapies for schizophrenia and other central nervous system (CNS) diseases. The new agreement calls for a one year extension of the initial five-year alliance and brings the total committed funding for the collaboration to over $75 million.
-
Supreme Court To Hear Case On Product Liability For Pharmaceutical Companies
The Supreme Court during the 2008-2009 term, which begins on Monday, will hear cases "testing the boundary between federal and state authority," such as a case that could determine whether "injured people can bring claims against allegedly defective drugs and other products to state courts," USA Today reports. The court likely will hear the case,
-
Biothera Develops New Method For Analyzing Beta Glucan Structure
Biothera has developed a new analytical method to characterize a key structural attribute of beta 1,3/1,6 glucans, which will aid researchers developing this immune-enhancing carbohydrate for pharmaceutical applications. The method was presented recently to scientists at both the International Carbohydrate Symposium in Oslo, Norway, and the American Chemical Society national meeting in Philadelphia.
-
Architectural Code Of Caffeine's Main Target In The Body Finally Cracked
Many receptor models used in drug design may not be useful after all It may very well be that models used for the design of new drugs have to be regarded as impractical. This is the sobering though important conclusion of the work of two Leiden University scientists published in Science this week. The editorial board of the renowned journal even decided to accelerate the publication on the crystal structure of the adenosine A2A receptor via Science Express.
-
BioMS Medical's Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review From Data Safety Monitoring Board
BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.
|
|
R S S F e e d s 
